Drug-resistant TB is TB that is resistant to one or more antituberculosis drugs, and TB that is resistant to at least both isoniazid and rifampin is called multidrug-resistant TB. Drug-resistant tuberculosis is determined by the patient’s retention of sputum specimens, culture of the tubercle bacilli in the laboratory, and determination of drug sensitivity tests to determine whether the tuberculosis is drug-resistant. Treatment of this type of tuberculosis is extremely difficult. It is not sufficiently rational in terms of the design of the treatment regimen, etc., and is highly susceptible to more and more severe drug resistance. For this reason, it is necessary to provide comprehensive treatment, including chemotherapy, immunotherapy, surgery, and interventional therapy, depending on the patient’s specific situation. Chemotherapy principles (1) In places where tuberculosis cultures and drug sensitivity tests are available, the results of drug sensitivity tests should be used as a guide to select new regimens containing more than three sensitive drugs; (2) In places where tuberculosis drug sensitivity tests are not available or where drug sensitivity tests are not available, new regimens should be selected based on the patient’s past drug history and the drug resistance situation in the region; (3) Adequate courses of treatment should be ensured, with the full course of treatment (4) The drug dose should be based on body weight; (5) After the chemotherapy regimen is determined, ensure that the regimen can be implemented as required, and include patients in the drug-resistant TB control strategy as much as possible to facilitate supervision and management; (6) Timely detection and proper management of adverse drug reactions to increase patient compliance with treatment.